Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Obesity (Silver Spring, Md.)|January 23, 2015
Effects of a 2-year behavioral weight loss intervention on sleep and mood in obese individuals treated in primary care practiceNasreen Alfaris, Thomas A Wadden, David B Sarwer, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 6, 2024
Qualitative and Psychometric Evaluation of 29-Item Patient-Reported Outcomes Measurement Information System® to Assess General Health-Related Quality of Life in Patients With Moderately to Severely Active Inflammatory Bowel DiseaseBruce E Sands, Julian Panés, Brian G Feagan, et al.
The New England Journal of Medicine|November 16, 2011
A two-year randomized trial of obesity treatment in primary care practiceThomas A Wadden, Sheri Volger, David B Sarwer, et al.
Diabetes|September 11, 2014
GLP-1 plays a limited role in improved glycemia shortly after Roux-en-Y gastric bypass: a comparison with intensive lifestyle modificationMarion L Vetter, Thomas A Wadden, Karen L Teff, et al.
Obesity Surgery|December 23, 2016
Changes in Fasting and Prandial Gut and Adiposity Hormones Following Vertical Sleeve Gastrectomy or Roux-en-Y-Gastric Bypass: an 18-Month Prospective StudyNaji Alamuddin, Marion L Vetter, Rexford S Ahima, et al.
Gastroenterology|March 20, 2025
Efficacy and Safety of Guselkumab Subcutaneous Induction and Maintenance in Participants With Moderately to Severely Active Crohn's Disease: Results From the Phase 3 GRAVITI StudyAilsa Hart, Remo Panaccione, Flavio Steinwurz, et al.
Inflammatory Bowel Diseases|May 1, 2026
Five-year efficacy and safety of guselkumab for moderately to severely active Crohn's disease: Results from the phase 2 GALAXI 1 trialAnita Afzali, Silvio Danese, Remo Panaccione, et al.
Lancet (London, England)|July 20, 2025
Efficacy and safety of intravenous induction and subcutaneous maintenance therapy with guselkumab for patients with Crohn's disease (GALAXI-2 and GALAXI-3): 48-week results from two phase 3, randomised, placebo and active comparator-controlled, double-blind, triple-dummy trialsRemo Panaccione, Brian G Feagan, Anita Afzali, et al.
BMJ Open Gastroenterology|March 23, 2026
Multiomic characterisation of the clinical efficacy of guselkumab induction therapy in ulcerative colitisAmy Hart, Sunandini Sridhar, Swati Venkat, et al.
Pageof 3